{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:31:36Z","timestamp":1790303496521,"version":"4.1.0"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T00:00:00Z","timestamp":1596931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T00:00:00Z","timestamp":1596931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12035-020-02035-9","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T19:04:47Z","timestamp":1596913487000},"page":"4667-4691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases"],"prefix":"10.1007","volume":"57","author":[{"given":"Giovanni","family":"Palermo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mazzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Della Vecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaldo","family":"Bonuccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Azuar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ceravolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-0556","authenticated-orcid":false,"given":"Filippo","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,9]]},"reference":[{"issue":"6","key":"2035_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918\u2013934","journal-title":"Cell"},{"issue":"7628","key":"2035_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/539179a","volume":"539","author":"MT Heemels","year":"2016","unstructured":"Heemels MT (2016) Neurodegenerative diseases. Nature 539(7628):179","journal-title":"Nature"},{"issue":"10","key":"2035_CR3","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.3390\/ijms19103082","volume":"19","author":"H Chi","year":"2018","unstructured":"Chi H, Chang HY, Sang TK (2018) Neuronal cell death mechanisms in major neurodegenerative diseases. Int J Mol Sci 19(10):3082","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2035_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jalz.2017.11.015","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, Toschi N, Baldacci F et al (2018) Alzheimer\u2019s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A\u03b21-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement 14(4):492\u2013501","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2035_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"2035_CR6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2035_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neubiorev.2019.04.014","volume":"102","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Xin Y, Meng S, He Z, Hu W (2019) Neurofilament light chain protein in neurodegenerative dementia: a systematic review and network meta-analysis. Neurosci Biobehav Rev 102:123\u2013138","journal-title":"Neurosci Biobehav Rev"},{"key":"2035_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2012.06.003","volume":"246","author":"NM Kanaan","year":"2013","unstructured":"Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA (2013) Axonal degeneration in Alzheimer\u2019s disease: when signaling abnormalities meet the axonal transport system. Exp Neurol 246:44\u201353","journal-title":"Exp Neurol"},{"key":"2035_CR9","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1242\/jcs.104729","volume":"125","author":"A Yuan","year":"2012","unstructured":"Yuan A, Rao MV, Veeranna NRA (2012) Neurofilaments at a glance. J Cell Sci 125:3257\u20133263","journal-title":"J Cell Sci"},{"issue":"1","key":"2035_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"91","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H (2016) Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 91(1):1\u20133","journal-title":"Neuron"},{"issue":"24","key":"2035_CR11","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00018-004-4268-8","volume":"61","author":"Q Liu","year":"2004","unstructured":"Liu Q, Xie F, Siedlak SL et al (2004) Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61(24):3057\u20133075","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2035_CR12","doi-asserted-by":"publisher","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","volume":"9","author":"A Yuan","year":"2017","unstructured":"Yuan A, Rao MV, Veeranna NRA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 9(4):a018309","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2\u20133","key":"2035_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000101843","volume":"4","author":"A Petzold","year":"2007","unstructured":"Petzold A, Keir G, Warren J, Fox N, Rossor MN (2007) A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 4(2\u20133):185\u2013194","journal-title":"Neurodegener Dis"},{"issue":"5","key":"2035_CR14","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","volume":"67","author":"LE Rosengren","year":"1996","unstructured":"Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkels\u00f8 C (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67(5):2013\u20132018","journal-title":"J Neurochem"},{"key":"2035_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2377-13-54","volume":"13","author":"M Landqvist Waldo","year":"2013","unstructured":"Landqvist Waldo M, Frizell Santillo A et al (2013) Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol 13:54","journal-title":"BMC Neurol"},{"issue":"8","key":"2035_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3(8):623\u2013636","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"2035_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall S, \u00d6hrfelt A, Constantinescu R et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. Arch Neurol 69(11):1445\u20131452","journal-title":"Arch Neurol"},{"issue":"11","key":"2035_CR18","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86(11):1240\u20131247","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2035_CR19","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1212\/NXI.0000000000000287","volume":"3","author":"T Vinther-Jensen","year":"2016","unstructured":"Vinther-Jensen T, B\u00f6rnsen L, Budtz-J\u00f8rgensen E et al (2016) Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm 3(6):e287","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2035_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuint.2017.05.010","volume":"108","author":"S Lista","year":"2017","unstructured":"Lista S, Toschi N, Baldacci F et al (2017) Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer\u2019s disease. Neurochem Int 108:355\u2013360","journal-title":"Neurochem Int"},{"issue":"1","key":"2035_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N et al (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. Jama Neurol 73(1):60\u201367","journal-title":"Jama Neurol"},{"issue":"2","key":"2035_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3233\/JAD-2010-090649","volume":"21","author":"JJ van Eijk","year":"2010","unstructured":"van Eijk JJ, van Everbroeck B, Abdo WF, Kremer BP, Verbeek MM (2010) CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J Alzheimers Dis 21(2):569\u2013576","journal-title":"J Alzheimers Dis"},{"key":"2035_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jocn.2018.09.031","volume":"60","author":"E Kanata","year":"2019","unstructured":"Kanata E, Golanska E, Villar-Piqu\u00e9 A et al (2019) Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. J Clin Neurosci 60:124\u2013127","journal-title":"J Clin Neurosci"},{"key":"2035_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","volume":"64","author":"JN Lycke","year":"1998","unstructured":"Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998) Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64:402\u2013404","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2035_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz A, Blennow K, Hagberg L et al (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn 17(8):761\u2013770","journal-title":"Expert Rev Mol Diagn"},{"issue":"11","key":"2035_CR26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamaneurol.2016.2038","volume":"73","author":"P Shahim","year":"2016","unstructured":"Shahim P, Tegner Y, Gustafsson B et al (2016) Neurochemical aftermath of repetitive mild traumatic brain injury. JAMA Neurol 73(11):1308\u20131315","journal-title":"JAMA Neurol"},{"key":"2035_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neulet.2018.12.042","volume":"698","author":"F Pujol-Calder\u00f3n","year":"2019","unstructured":"Pujol-Calder\u00f3n F, Portelius E, Zetterberg H, Blennow K, Rosengren LE, H\u00f6glund K (2019) Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci Lett 698:58\u201363","journal-title":"Neurosci Lett"},{"issue":"6","key":"2035_CR28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/acn3.790","volume":"6","author":"M Pawlitzki","year":"2019","unstructured":"Pawlitzki M, Butryn M, Kirchner F et al (2019) CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis. Ann Clin Transl Neurol 6(6):1134\u20131137","journal-title":"Ann Clin Transl Neurol"},{"issue":"21","key":"2035_CR29","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck T, Farahmand B, Bartlett JW et al (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83(21):1945\u20131953","journal-title":"Neurology"},{"key":"2035_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O et al (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:56\u201366","journal-title":"Neuron"},{"issue":"9","key":"2035_CR31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. Jama Neurol 76(9):1035\u20131048","journal-title":"Jama Neurol"},{"issue":"3","key":"2035_CR32","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","volume":"93","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K et al (2019) Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology 93(3):e252\u2013e260","journal-title":"Neurology"},{"issue":"6","key":"2035_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo JL, Ayton S, Batrla R et al (2018) Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol 136(6):821\u2013853","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2035_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jalz.2012.05.2116","volume":"8","author":"H Hampel","year":"2012","unstructured":"Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer\u2019s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8(4):312\u2013336","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2035_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jshs.2016.08.007","volume":"5","author":"F Baldacci","year":"2016","unstructured":"Baldacci F, Lista S, Garaci F, Bonuccelli U, Toschi N, Hampel H (2016) Biomarker-guided classification scheme of neurodegenerative diseases. J Sport Health Sci 5(4):383\u2013387","journal-title":"J Sport Health Sci"},{"issue":"7","key":"2035_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel H, Frank R, Broich K et al (2010) Biomarkers for Alzheimer\u2019s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9(7):560\u2013574","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2035_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131\u2013144","journal-title":"Nat Rev Neurol"},{"issue":"s1","key":"2035_CR38","doi-asserted-by":"publisher","first-page":"S271","DOI":"10.3233\/JAD-179926","volume":"64","author":"H Zetterberg","year":"2018","unstructured":"Zetterberg H, Blennow K (2018) From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer\u2019s disease. J Alzheimers Dis 64(s1):S271\u2013S279","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"2035_CR39","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655\u20131661","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"2035_CR40","doi-asserted-by":"publisher","first-page":"e75091","DOI":"10.1371\/journal.pone.0075091","volume":"8","author":"J Gaiottino","year":"2013","unstructured":"Gaiottino J, Norgren N, Dobson R et al (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 8(9):e75091","journal-title":"PLoS One"},{"issue":"4","key":"2035_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/14737159.2020.1731306","volume":"20","author":"F Baldacci","year":"2020","unstructured":"Baldacci F, Mazzucchi S, Della Vecchia A et al (2020) The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Rev Mol Diagn 20(4):421\u2013441","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"2035_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med (Maywood) 243(3):213\u2013221","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"2035_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89\u201395","journal-title":"Clin Pharmacol Ther"},{"key":"2035_CR44","first-page":"303","volume":"163","author":"XH Chen","year":"2011","unstructured":"Chen XH, Huang S, Kerr D (2011) Biomarkers in clinical medicine. IARC Sci Publ 163:303\u2013322","journal-title":"IARC Sci Publ"},{"key":"2035_CR45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"2035_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269","journal-title":"Alzheimers Dement"},{"key":"2035_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:280\u2013292","journal-title":"Alzheimers Dement"},{"key":"2035_CR48","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:270\u2013279","journal-title":"Alzheimers Dement"},{"key":"2035_CR49","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol 13:614\u2013629","journal-title":"Lancet Neurol"},{"issue":"Suppl","key":"2035_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0022-510X(94)90191-0","volume":"124","author":"BR Brooks","year":"1994","unstructured":"Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases\/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial \u201cClinical limits of amyotrophic lateral sclerosis\u201d workshop contributors. J Neurol Sci 124(Suppl):96\u2013107","journal-title":"J Neurol Sci"},{"key":"2035_CR51","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/archneurol.2012.254","volume":"69","author":"J Costa","year":"2012","unstructured":"Costa J, Swash M, de Carvalho M (2012) Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol 69:1410\u20131416","journal-title":"Arch Neurol"},{"issue":"11","key":"2035_CR52","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1474-4422(16)30199-5","volume":"15","author":"A Al-Chalabi","year":"2016","unstructured":"Al-Chalabi A, Hardiman O, Kiernan MC, Chi\u00f2 A, Rix-Brooks B, van den Berg LH (2016) Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 15(11):1182\u20131194","journal-title":"Lancet Neurol"},{"issue":"5","key":"2035_CR53","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"IG McKeith","year":"1996","unstructured":"McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113\u20131124","journal-title":"Neurology"},{"issue":"12","key":"2035_CR54","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863\u20131872","journal-title":"Neurology"},{"issue":"1","key":"2035_CR55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89(1):88\u2013100","journal-title":"Neurology"},{"key":"2035_CR56","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","volume":"51","author":"D Neary","year":"1998","unstructured":"Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546\u20131554","journal-title":"Neurology"},{"key":"2035_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(10)70299-4","volume":"10","author":"O Piguet","year":"2011","unstructured":"Piguet O, Hornberger M, Mioshi E, Hodges JR (2011) Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 10:162\u2013172","journal-title":"Lancet Neurol"},{"key":"2035_CR58","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006\u20131014","journal-title":"Neurology"},{"key":"2035_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 51:745\u2013752","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2035_CR60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33\u201339","journal-title":"Arch Neurol"},{"issue":"12","key":"2035_CR61","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease: MDS-PD clinical diagnostic criteria. Mov Disord 30(12):1591\u20131601","journal-title":"Mov Disord"},{"key":"2035_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1\u20139","journal-title":"Neurology"},{"issue":"9","key":"2035_CR63","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670\u2013676","journal-title":"Neurology"},{"issue":"5","key":"2035_CR64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5):496\u2013503","journal-title":"Neurology"},{"key":"2035_CR65","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864","journal-title":"Mov Disord"},{"key":"2035_CR66","unstructured":"World Health Organization (2003) WHO manual for surveillance of human transmissible spongiform encephalopathies, including variant Creutzfeldt-Jakob disease https:\/\/apps.who.int\/iris\/handle\/10665\/42656 [Accessed 30 Jan 2003]"},{"key":"2035_CR67","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2015.8.FOCUS15328","volume":"39","author":"M Manix","year":"2015","unstructured":"Manix M, Kalakoti P, Henry M et al (2015) Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus 39:E2","journal-title":"Neurosurg Focus"},{"issue":"2","key":"2035_CR68","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11306-012-0482-9","volume":"9","author":"J Xia","year":"2013","unstructured":"Xia J, Broadhurst DI, Wilson M, Wishart DS (2013) Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 9(2):280\u2013299","journal-title":"Metabolomics"},{"issue":"5","key":"2035_CR69","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S et al (2016) Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol 15(5):455\u2013532","journal-title":"Lancet Neurol"},{"key":"2035_CR70","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB (2018) Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun 11:156\u2013164","journal-title":"Contemp Clin Trials Commun"},{"issue":"3","key":"2035_CR71","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3233\/JAD-170536","volume":"62","author":"B Dubois","year":"2018","unstructured":"Dubois B (2018) The emergence of a new conceptual framework for Alzheimer\u2019s disease. J Alzheimers Dis 62(3):1059\u20131066","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2035_CR72","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol 71(4):266\u2013273","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"2035_CR73","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2016) A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539\u2013547","journal-title":"Neurology"},{"issue":"4","key":"2035_CR74","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2035_CR75","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, O\u2019Bryant SE, Molinuevo JL et al (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 14(11):639\u2013652","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2035_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","volume":"7","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Leuzy A, Lim YM et al (2019) Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun 7(1):5","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"2035_CR77","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. Jama Neurol 74(5):557\u2013566","journal-title":"Jama Neurol"},{"issue":"8","key":"2035_CR78","doi-asserted-by":"publisher","first-page":"e0135886","DOI":"10.1371\/journal.pone.0135886","volume":"10","author":"M V\u00e5gberg","year":"2015","unstructured":"V\u00e5gberg M, Norgren N, Dring A et al (2015) Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. PLoS One 10(8):e0135886","journal-title":"PLoS One"},{"issue":"1","key":"2035_CR79","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M, Pirpamer L, Hofer E et al (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 11(1):812","journal-title":"Nat Commun"},{"key":"2035_CR80","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.dadm.2019.08.009","volume":"11","author":"LM Forgrave","year":"2019","unstructured":"Forgrave LM, Ma M, Best JR, DeMarco ML (2019) The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer\u2019s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement (Amst) 11:730\u2013743","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"2035_CR81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Ermann N, Andreasson U et al (2018) Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimers Res Ther 10(1):71","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"2035_CR82","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 76(7):791\u2013799","journal-title":"JAMA Neurol"},{"key":"2035_CR83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2017.06.002","volume":"58","author":"JB Pereira","year":"2017","unstructured":"Pereira JB, Westman E, Hansson O, Alzheimer\u2019s Disease Neuroimaging Initiative (2017) Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer\u2019s disease. Neurobiol Aging 58:14\u201329","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2035_CR84","doi-asserted-by":"publisher","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"YS Lin","year":"2018","unstructured":"Lin YS, Lee WJ, Wang SJ, Fuh JL (2018) Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 8(1):17368","journal-title":"Sci Rep"},{"issue":"4","key":"2035_CR85","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3233\/JAD-190615","volume":"72","author":"SY Wang","year":"2019","unstructured":"Wang SY, Chen W, Xu W et al (2019) Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimers Dis 72(4):1353\u20131361","journal-title":"J Alzheimers Dis"},{"key":"2035_CR86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","volume":"650","author":"W Zhou","year":"2017","unstructured":"Zhou W, Zhang J, Ye F et al (2017) Plasma neurofilament light chain levels in Alzheimer\u2019s disease. Neurosci Lett 650:60\u201364","journal-title":"Neurosci Lett"},{"key":"2035_CR87","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.dadm.2019.08.002","volume":"11","author":"AL Benedet","year":"2019","unstructured":"Benedet AL, Ashton NJ, Pascoal TA et al (2019) Plasma neurofilament light associates with Alzheimer\u2019s disease metabolic decline in amyloid-positive individuals. Alzheimers Dement (Amst) 11:679\u2013689","journal-title":"Alzheimers Dement (Amst)"},{"key":"2035_CR88","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neurobiolaging.2019.03.016","volume":"79","author":"M Timmers","year":"2019","unstructured":"Timmers M, Tesseur I, Bogert J et al (2019) Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer\u2019s disease. Neurobiol Aging 79:131\u2013141","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2035_CR89","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med 25(2):277\u2013283","journal-title":"Nat Med"},{"issue":"17","key":"2035_CR90","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.18632\/aging.102220","volume":"11","author":"H Hu","year":"2019","unstructured":"Hu H, Chen KL, Ou YN et al (2019) Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging (Albany NY) 11(17):6904\u20136914","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"2035_CR91","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3233\/JAD-180025","volume":"63","author":"P Chatterjee","year":"2018","unstructured":"Chatterjee P, Goozee K, Sohrabi HR et al (2018) Association of plasma neurofilament light chain with neocortical amyloid-\u03b2 load and cognitive performance in cognitively normal elderly participants. J Alzheimers Dis 63(2):479\u2013487","journal-title":"J Alzheimers Dis"},{"key":"2035_CR92","doi-asserted-by":"crossref","unstructured":"Mayeli M, Mirshahvalad SM, Aghamollaii V, Tafakhori A, Abdolalizadeh A, Rahmani F (2019) Plasma neurofilament light chain levels are associated with cortical hypometabolism in Alzheimer disease signature regions. J Neuropathol Exp Neurol 78(8): 709\u2013716","DOI":"10.1093\/jnen\/nlz054"},{"issue":"21","key":"2035_CR93","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston PSJ, Poole T, Ryan NS et al (2017) Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89(21):2167\u20132175","journal-title":"Neurology"},{"key":"2035_CR94","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456\u20132477","journal-title":"Brain"},{"issue":"4","key":"2035_CR95","doi-asserted-by":"publisher","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol 10(4):a033118","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2035_CR96","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","volume":"386","author":"J Bang","year":"2015","unstructured":"Bang J, Spina S, Miller BL (2015) Frontotemporal dementia. Lancet 386:1672\u20131682","journal-title":"Lancet"},{"key":"2035_CR97","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.24885","volume":"81","author":"EG Spinelli","year":"2017","unstructured":"Spinelli EG, Mandelli ML, Miller ZA et al (2017) Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 81:430\u2013443","journal-title":"Ann Neurol"},{"key":"2035_CR98","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","volume":"18","author":"MJ Strong","year":"2017","unstructured":"Strong MJ, Abrahams S, Goldstein LH et al (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18:153\u2013174","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"8","key":"2035_CR99","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","volume":"8","author":"R Rademakers","year":"2012","unstructured":"Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8(8):423\u2013434","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"2035_CR100","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/brain\/awaa018","volume":"143","author":"S Ducharme","year":"2020","unstructured":"Ducharme S, Dols A, Laforce R et al (2020) Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 143(6):1632\u20131650","journal-title":"Brain"},{"issue":"7","key":"2035_CR101","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nrneurol.2017.75","volume":"13","author":"LH Meeter","year":"2017","unstructured":"Meeter LH, Kaat LD, Rohrer JD, van Swieten JC (2017) Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 13(7):406\u2013419","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2035_CR102","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/nan.12530","volume":"45","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, van Swieten JC, Boxer AL, Rohrer JD (2019) Review: Fluid biomarkers for frontotemporal dementias. Neuropathol Appl Neurobiol 45(1):81\u201387","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"2035_CR103","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.dadm.2015.11.001","volume":"1","author":"YA Pijnenburg","year":"2015","unstructured":"Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE (2015) Discriminative and prognostic potential of cerebrospinal fluid phosphoTau\/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst) 1(4):505\u2013512","journal-title":"Alzheimers Dement (Amst)"},{"key":"2035_CR104","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1474-4422(19)30354-0","volume":"18","author":"E Ende","year":"2019","unstructured":"Ende E, Meeter L, Poos J et al (2019) Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 18:1103\u20131111","journal-title":"Lancet Neurol"},{"key":"2035_CR105","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1212\/WNL.0000000000003688","volume":"88","author":"P Steinacker","year":"2017","unstructured":"Steinacker P, Semler E, Anderl-Straub S et al (2017) Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology 88:961\u2013969","journal-title":"Neurology"},{"key":"2035_CR106","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpsychires.2019.03.019","volume":"113","author":"MR Al Shweiki","year":"2019","unstructured":"Al Shweiki MR, Steinacker P, Oeckl P et al (2019) Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res 113:137\u2013140","journal-title":"J Psychiatr Res"},{"issue":"1","key":"2035_CR107","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00415-019-09567-8","volume":"267","author":"K Katisko","year":"2020","unstructured":"Katisko K, Cajanus A, J\u00e4\u00e4skel\u00e4inen O et al (2020) Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol 267(1):162\u2013167","journal-title":"J Neurol"},{"key":"2035_CR108","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jnnp-2015-312972","volume":"87","author":"C Wilke","year":"2016","unstructured":"Wilke C, Preische O, Deuschle C et al (2016) Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry 87:1270\u20131272","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"2035_CR109","doi-asserted-by":"publisher","first-page":"e1390","DOI":"10.1212\/WNL.0000000000006318","volume":"91","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Anderl-Straub S, Diehl-Schmid J et al (2018) Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology 91(15):e1390\u2013e1401","journal-title":"Neurology"},{"key":"2035_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-190838","volume":"72","author":"JA Matias-Guiu","year":"2019","unstructured":"Matias-Guiu JA, Gomez-Pinedo U, Forero L et al (2019) Plasma neurofilament light chain in primary progressive aphasia and related disorders: clinical significance and metabolic correlates. J Alzheimers Dis 72:1\u201310","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"2035_CR111","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.clineuro.2011.11.026","volume":"114","author":"E Cellura","year":"2012","unstructured":"Cellura E, Spataro R, Taiello AC, La Bella V (2012) Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 114(6):550\u2013554","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"2035_CR112","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(08)70293-X","volume":"8","author":"MR Turner","year":"2009","unstructured":"Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8(1):94\u2013109","journal-title":"Lancet Neurol"},{"issue":"5\u20136","key":"2035_CR113","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/21678421.2014.884592","volume":"15","author":"S Lehnert","year":"2014","unstructured":"Lehnert S, Costa J, de Carvalho M et al (2014) Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 15(5\u20136):344\u2013350","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"2035_CR114","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.24470","volume":"51","author":"MR Turner","year":"2015","unstructured":"Turner MR, Benatar M (2015) Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve 51(1):14\u201318","journal-title":"Muscle Nerve"},{"issue":"10","key":"2035_CR115","doi-asserted-by":"publisher","first-page":"e0164625","DOI":"10.1371\/journal.pone.0164625","volume":"11","author":"Z Xu","year":"2016","unstructured":"Xu Z, Henderson RD, David M, McCombe PA (2016) Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One 11(10):e0164625","journal-title":"PLoS One"},{"issue":"1","key":"2035_CR116","first-page":"3","volume":"87","author":"MR Turner","year":"2016","unstructured":"Turner MR, Gray E (2016) Are neurofilaments heading for the ALS clinic? J Neurol Neurosurg Psychiatry 87(1):3\u20134","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2035_CR117","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1212\/01.wnl.0000203120.85850.54","volume":"66","author":"J Brettschneider","year":"2006","unstructured":"Brettschneider J, Petzold A, S\u00fcssmuth SD, Ludolph AC, Tumani H (2006) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66(6):852\u2013856","journal-title":"Neurology"},{"issue":"4","key":"2035_CR118","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.20965","volume":"60","author":"H Lin","year":"2006","unstructured":"Lin H, Schlaepfer WW (2006) Role of neurofilament aggregation in motor neuron disease. Ann Neurol 60(4):399\u2013406","journal-title":"Ann Neurol"},{"issue":"1","key":"2035_CR119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/00005072-198801000-00002","volume":"47","author":"DG Munoz","year":"1988","unstructured":"Munoz DG, Greene C, Perl DP, Selkoe DJ (1988) Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 47(1):9\u201318","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6526","key":"2035_CR120","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/375061a0","volume":"375","author":"JF Collard","year":"1995","unstructured":"Collard JF, C\u00f4t\u00e9 F, Julien JP (1995) Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 375(6526):61\u201364","journal-title":"Nature"},{"issue":"4","key":"2035_CR121","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/0896-6273(94)90263-1","volume":"13","author":"MK Lee","year":"1994","unstructured":"Lee MK, Marszalek JR, Cleveland DW (1994) A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 13(4):975\u2013988","journal-title":"Neuron"},{"issue":"4","key":"2035_CR122","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1523\/JNEUROSCI.19-04-01273.1999","volume":"19","author":"R Ca\u00f1ete-Soler","year":"1999","unstructured":"Ca\u00f1ete-Soler R, Silberg DG, Gershon MD, Schlaepfer WW (1999) Mutation in neurofilament transgene implicates RNA processing in the pathogenesis of neurodegenerative disease. J Neurosci 19(4):1273\u20131283","journal-title":"J Neurosci"},{"issue":"17","key":"2035_CR123","doi-asserted-by":"publisher","first-page":"7662","DOI":"10.1523\/JNEUROSCI.22-17-07662.2002","volume":"22","author":"Z Nie","year":"2002","unstructured":"Nie Z, Wu J, Zhai J et al (2002) Untranslated element in neurofilament mRNA has neuropathic effect on motor neurons of transgenic mice. J Neurosci 22(17):7662\u20137670","journal-title":"J Neurosci"},{"issue":"24","key":"2035_CR124","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1093\/hmg\/ddm272","volume":"16","author":"J Zhai","year":"2007","unstructured":"Zhai J, Lin H, Julien JP, Schlaepfer WW (2007) Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. Hum Mol Genet 16(24):3103\u20133116","journal-title":"Hum Mol Genet"},{"issue":"23","key":"2035_CR125","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1093\/hmg\/ddi392","volume":"14","author":"H Lin","year":"2005","unstructured":"Lin H, Zhai J, Schlaepfer WW (2005) RNA-binding protein is involved in aggregation of light neurofilament protein and is implicated in the pathogenesis of motor neuron degeneration. Hum Mol Genet 14(23):3643\u20133659","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2035_CR126","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/jnr.490300123","volume":"30","author":"D Watson","year":"1991","unstructured":"Watson D (1991) Regional variation in the abundance of axonal cytoskeletal proteins. J Neurosci Res 30(1):226\u2013231","journal-title":"J Neurosci Res"},{"issue":"4","key":"2035_CR127","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00415-009-0131-z","volume":"256","author":"TS Reijn","year":"2009","unstructured":"Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM (2009) CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 256(4):615\u2013619","journal-title":"J Neurol"},{"issue":"1","key":"2035_CR128","first-page":"12","volume":"87","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Feneberg E, Weishaupt J et al (2016) Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12\u201320","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"2035_CR129","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1468-1331.2012.03777.x","volume":"19","author":"R Tortelli","year":"2012","unstructured":"Tortelli R, Ruggieri M, Cortese R et al (2012) Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 19(12):1561\u20131567","journal-title":"Eur J Neurol"},{"issue":"12","key":"2035_CR130","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1468-1331.2007.01972.x","volume":"14","author":"H Zetterberg","year":"2007","unstructured":"Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM (2007) Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 14(12):1329\u20131333","journal-title":"Eur J Neurol"},{"issue":"1","key":"2035_CR131","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.12421","volume":"22","author":"R Tortelli","year":"2015","unstructured":"Tortelli R, Copetti M, Ruggieri M et al (2015) Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol 22(1):215\u2013218","journal-title":"Eur J Neurol"},{"key":"2035_CR132","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3389\/fneur.2018.01167","volume":"9","author":"K Poesen","year":"2019","unstructured":"Poesen K, Van Damme P (2019) Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 9:1167","journal-title":"Front Neurol"},{"issue":"7","key":"2035_CR133","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/acn3.212","volume":"2","author":"RA Menke","year":"2015","unstructured":"Menke RA, Gray E, Lu CH et al (2015) CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2(7):748\u2013755","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2035_CR134","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1212\/WNL.0000000000004761","volume":"90","author":"E Feneberg","year":"2018","unstructured":"Feneberg E, Oeckl P, Steinacker P et al (2018) Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90(1):e22\u2013e30","journal-title":"Neurology"},{"issue":"3","key":"2035_CR135","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/nan.12511","volume":"45","author":"B Gille","year":"2019","unstructured":"Gille B, De Schaepdryver M, Goossens J et al (2019) Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 45(3):291\u2013304","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"22","key":"2035_CR136","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247\u20132257","journal-title":"Neurology"},{"issue":"5","key":"2035_CR137","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","volume":"74","author":"A Gaiani","year":"2017","unstructured":"Gaiani A, Martinelli I, Bello L et al (2017) Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. Jama Neurol 74(5):525\u2013532","journal-title":"Jama Neurol"},{"issue":"1\u20132","key":"2035_CR138","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/21678421.2016.1241279","volume":"18","author":"P Steinacker","year":"2017","unstructured":"Steinacker P, Huss A, Mayer B et al (2017) Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener 18(1\u20132):112\u2013119","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"2035_CR139","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde F, Steinacker P, Weishaupt JH et al (2019) Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 90(2):157\u2013164","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"2035_CR140","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/ene.14063","volume":"27","author":"E Thouvenot","year":"2020","unstructured":"Thouvenot E, Demattei C, Lehmann S et al (2020) Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol 27(2):251\u2013257","journal-title":"Eur J Neurol"},{"issue":"24","key":"2035_CR141","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","volume":"88","author":"K Poesen","year":"2017","unstructured":"Poesen K, De Schaepdryver M, Stubendorff B et al (2017) Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88(24):2302\u20132309","journal-title":"Neurology"},{"issue":"4","key":"2035_CR142","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp-2019-322309","volume":"91","author":"M De Schaepdryver","year":"2020","unstructured":"De Schaepdryver M, Lunetta C, Tarlarini C et al (2020) Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 91(4):436\u2013437","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2035_CR143","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ana.24552","volume":"79","author":"P Weydt","year":"2016","unstructured":"Weydt P, Oeckl P, Huss A et al (2016) Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 79(1):152\u2013158","journal-title":"Ann Neurol"},{"issue":"1","key":"2035_CR144","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.25276","volume":"84","author":"M Benatar","year":"2018","unstructured":"Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A (2018) Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 84(1):130\u2013139","journal-title":"Ann Neurol"},{"issue":"9","key":"2035_CR145","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC et al (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266(9):2129\u20132136","journal-title":"J Neurol"},{"issue":"4","key":"2035_CR146","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nn.4508","volume":"20","author":"DR Corey","year":"2017","unstructured":"Corey DR (2017) Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci 20(4):497\u2013499","journal-title":"Nat Neurosci"},{"key":"2035_CR147","doi-asserted-by":"publisher","first-page":"175628641984605","DOI":"10.1177\/1756286419846058","volume":"12","author":"CD Wurster","year":"2019","unstructured":"Wurster CD, G\u00fcnther R, Steinacker P et al (2019) Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord 12:1756286419846058","journal-title":"Ther Adv Neurol Disord"},{"issue":"23","key":"2035_CR148","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1212\/WNL.0000000000000507","volume":"82","author":"P Fratta","year":"2014","unstructured":"Fratta P, Nirmalananthan N, Masset L et al (2014) Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology 82(23):2077\u20132084","journal-title":"Neurology"},{"key":"2035_CR149","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/mds.25327","volume":"28","author":"G Respondek","year":"2013","unstructured":"Respondek G, Roeber S, Kretzschmar H et al (2013) Accuracy of the National Institute for Neurological Disorders and Stroke\/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 28:504\u2013509","journal-title":"Mov Disord"},{"issue":"6","key":"2035_CR150","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G (2016) Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86(6):566\u2013576","journal-title":"Neurology"},{"issue":"4","key":"2035_CR151","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","volume":"89","author":"G Rizzo","year":"2018","unstructured":"Rizzo G, Arcuti S, Copetti M et al (2018) Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 89(4):358\u2013366","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"2035_CR152","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/brain\/awz189","volume":"142","author":"Y Miki","year":"2019","unstructured":"Miki Y, Foti SC, Asi YT et al (2019) Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain 142(9):2813\u20132827","journal-title":"Brain"},{"issue":"5","key":"2035_CR153","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neurobiolaging.2006.03.010","volume":"28","author":"WF Abdo","year":"2007","unstructured":"Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson\u2019s disease. Neurobiol Aging 28(5):742\u2013747","journal-title":"Neurobiol Aging"},{"key":"2035_CR154","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fneur.2015.00091","volume":"6","author":"MK Herbert","year":"2015","unstructured":"Herbert MK, Aerts MB, Beenes M et al (2015) CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol 6:91","journal-title":"Front Neurol"},{"key":"2035_CR155","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00234-012-1009-9","volume":"54","author":"K Tsukamoto","year":"2012","unstructured":"Tsukamoto K, Matsusue E, Kanasaki Y et al (2012) Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson\u2019s disease: evaluation by 3.0-T MR imaging. Neuroradiology 54:947\u2013955","journal-title":"Neuroradiology"},{"key":"2035_CR156","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930\u2013937","journal-title":"Neurology"},{"issue":"6","key":"2035_CR157","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P et al (2019) CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 18(6):573\u2013586","journal-title":"Lancet Neurol"},{"issue":"13","key":"2035_CR158","doi-asserted-by":"publisher","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, van Rumund A, Oeckl P et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92(13):e1479\u2013e1486","journal-title":"Neurology"},{"issue":"2","key":"2035_CR159","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.27897","volume":"35","author":"LP Oosterveld","year":"2020","unstructured":"Oosterveld LP, Verberk IMW, Majbour NK et al (2020) CSF or serum neurofilament light added to \u03b1-synuclein panel discriminates Parkinson\u2019s from controls. Mov Disord 35(2):288\u2013295","journal-title":"Mov Disord"},{"issue":"1","key":"2035_CR160","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","volume":"15","author":"ASL Ng","year":"2020","unstructured":"Ng ASL, Tan YJ, Yong ACW et al (2020) Utility of plasma neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease. Mol Neurodegener 15(1):33","journal-title":"Mol Neurodegener"},{"key":"2035_CR161","doi-asserted-by":"publisher","unstructured":"Mollenhauer B, Dakna M, Liu T-Y et al (2019) Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression. bioRxiv. Cold Spring Harbor Laboratory; Epub:762237. https:\/\/doi.org\/10.1101\/762237","DOI":"10.1101\/762237"},{"issue":"11","key":"2035_CR162","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin CH, Li CH, Yang KC et al (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93(11):e1104\u2013e1111","journal-title":"Neurology"},{"key":"2035_CR163","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216\u2013225","journal-title":"Ann Clin Transl Neurol"},{"key":"2035_CR164","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","volume":"56","author":"L Donker Kaat","year":"2018","unstructured":"Donker Kaat L, Meeter LH, Chiu WZ et al (2018) Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord 56:98\u2013101","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"2035_CR165","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s00415-018-8893-9","volume":"265","author":"C Wilke","year":"2018","unstructured":"Wilke C, Bender F, Hayer SN et al (2018) Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol 265(7):1618\u20131624","journal-title":"J Neurol"},{"key":"2035_CR166","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000227891.25592.8c","volume":"67","author":"WF Abdo","year":"2006","unstructured":"Abdo WF, van de Warrenburg BP, Munneke M et al (2006) CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 67:474\u2013479","journal-title":"Neurology"},{"issue":"1","key":"2035_CR167","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-019-0338-0","volume":"14","author":"QF Li","year":"2019","unstructured":"Li QF, Dong Y, Yang L et al (2019) Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. Mol Neurodegener 14(1):39","journal-title":"Mol Neurodegener"},{"key":"2035_CR168","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fncel.2018.00366","volume":"12","author":"AM Zeitlberger","year":"2018","unstructured":"Zeitlberger AM, Thomas-Black G, Garcia-Moreno H et al (2018) Plasma markers of neurodegeneration are raised in Friedreich\u2019s ataxia. Front Cell Neurosci 12:366","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"2035_CR169","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1007\/s00415-020-09722-6","volume":"267","author":"SN Hayer","year":"2020","unstructured":"Hayer SN, Liepelt I, Barro C et al (2020) NfL and pNfH are increased in Friedreich\u2019s ataxia. J Neurol 267(5):1420\u20131430","journal-title":"J Neurol"},{"issue":"R1","key":"2035_CR170","doi-asserted-by":"publisher","first-page":"R98","DOI":"10.1093\/hmg\/ddq148","volume":"19","author":"CD Johnson","year":"2010","unstructured":"Johnson CD, Davidson BL (2010) Huntington\u2019s disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet 19(R1):R98\u2013R102","journal-title":"Hum Mol Genet"},{"key":"2035_CR171","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Primers 1:15005","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2035_CR172","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/practneurol-2013-000790","volume":"15","author":"D Craufurd","year":"2015","unstructured":"Craufurd D, MacLeod R, Frontali M et al (2015) Diagnostic genetic testing for Huntington\u2019s disease. Pract Neurol 15(1):80\u201384","journal-title":"Pract Neurol"},{"issue":"3","key":"2035_CR173","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","volume":"15","author":"R Constantinescu","year":"2009","unstructured":"Constantinescu R, Romer M, Oakes D, Rosengren L, Kieburtz K (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington\u2019s disease. Parkinsonism Relat Disord 15(3):245\u2013248","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2035_CR174","doi-asserted-by":"publisher","first-page":"e0172762","DOI":"10.1371\/journal.pone.0172762","volume":"12","author":"V Niemel\u00e4","year":"2017","unstructured":"Niemel\u00e4 V, Landtblom AM, Blennow K, Sundblom J (2017) Tau or neurofilament light-which is the more suitable biomarker for Huntington\u2019s disease? PLoS One 12(2):e0172762","journal-title":"PLoS One"},{"issue":"4","key":"2035_CR175","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204\u2013216","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"2035_CR176","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest 125(5):1979\u20131986","journal-title":"J Clin Invest"},{"issue":"8","key":"2035_CR177","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol 16(8):601\u2013609","journal-title":"Lancet Neurol"},{"key":"2035_CR178","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","volume":"1780","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Byrne LM, Wild EJ (2018) Biofluid biomarkers in Huntington\u2019s disease. Methods Mol Biol 1780:329\u2013396","journal-title":"Methods Mol Biol"},{"issue":"8","key":"2035_CR179","doi-asserted-by":"publisher","first-page":"e717","DOI":"10.1212\/WNL.0000000000005005","volume":"90","author":"EB Johnson","year":"2018","unstructured":"Johnson EB, Byrne LM, Gregory S et al (2018) Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology 90(8):e717\u2013e723","journal-title":"Neurology"},{"issue":"458","key":"2035_CR180","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne LM, Rodrigues FB, Johnson EB et al (2018) Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci Transl Med 10(458):eaat7108","journal-title":"Sci Transl Med"},{"issue":"1","key":"2035_CR181","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(19)30615-2","volume":"20","author":"L Uttley","year":"2020","unstructured":"Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (2020) Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis 20(1):e2\u2013e10","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2035_CR182","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W","volume":"46","author":"P Parchi","year":"1999","unstructured":"Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46(2):224\u2013233","journal-title":"Ann Neurol"},{"key":"2035_CR183","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1093\/brain\/awp191","volume":"132","author":"I Zerr","year":"2009","unstructured":"Zerr I, Kallenberg K, Summers DM et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132:2659\u20132668","journal-title":"Brain"},{"key":"2035_CR184","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.3390\/ijms12096281","volume":"12","author":"G Zanusso","year":"2011","unstructured":"Zanusso G, Fiorini M, Ferrari S et al (2011) Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. Int J Mol Sci 12:6281\u20136292","journal-title":"Int J Mol Sci"},{"key":"2035_CR185","doi-asserted-by":"publisher","first-page":"38737","DOI":"10.1038\/srep38737","volume":"6","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Blennow K, Halbgebauer S et al (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep 6:38737","journal-title":"Sci Rep"},{"issue":"6","key":"2035_CR186","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jalz.2017.12.008","volume":"14","author":"I Zerr","year":"2018","unstructured":"Zerr I, Schmitz M, Karch A et al (2018) Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement 14(6):751\u2013763","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2035_CR187","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-017-0331-1","volume":"10","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh S, Capellari S, Stanzani-Maserati M et al (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther 10(1):3","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"2035_CR188","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/jnnp-2017-317793","volume":"89","author":"AGB Thompson","year":"2018","unstructured":"Thompson AGB, Luk C, Heslegrave AJ et al (2018) Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry 89(9):955\u2013961","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2035_CR189","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/ene.13389","volume":"24","author":"GG Kovacs","year":"2017","unstructured":"Kovacs GG, Andreasson U, Liman V et al (2017) Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol 24(11):1326\u20131e77","journal-title":"Eur J Neurol"},{"issue":"8","key":"2035_CR190","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamaneurol.2019.1071","volume":"76","author":"AM Staffaroni","year":"2019","unstructured":"Staffaroni AM, Kramer AO, Casey M et al (2019) Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. JAMA Neurol 76(8):969\u2013977","journal-title":"JAMA Neurol"},{"key":"2035_CR191","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/B978-0-444-63945-5.00013-1","volume":"153","author":"A Ladogana","year":"2018","unstructured":"Ladogana A, Kovacs GG (2018) Genetic Creutzfeldt-Jakob disease. Handb Clin Neurol 153:219\u2013242","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"2035_CR192","doi-asserted-by":"publisher","first-page":"a033134","DOI":"10.1101\/cshperspect.a033134","volume":"10","author":"MO Kim","year":"2018","unstructured":"Kim MO, Takada LT, Wong K, Forner SA, Geschwind MD (2018) Genetic PrP prion diseases. Cold Spring Harb Perspect Biol 10(5):a033134","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"2035_CR193","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1474-4422(19)30403-X","volume":"19","author":"SM Vallabh","year":"2020","unstructured":"Vallabh SM, Minikel EV, Schreiber SL, Lander ES (2020) Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurol 19(4):361\u2013368","journal-title":"Lancet Neurol"},{"issue":"7","key":"2035_CR194","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14737159.2019.1627202","volume":"19","author":"F Baldacci","year":"2019","unstructured":"Baldacci F, Lista S, Vergallo A, Palermo G, Giorgi FS, Hampel H (2019) A frontline defense against neurodegenerative diseases: the development of early disease detection methods. Expert Rev Mol Diagn 19(7):559\u2013563","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"2035_CR195","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton NJ, Hye A, Rajkumar AP et al (2020) An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol 16(5):265\u2013284","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2035_CR196","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12603-013-0003-1","volume":"17","author":"H Hampel","year":"2013","unstructured":"Hampel H, Lista S (2013) Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging 17(1):54\u201363","journal-title":"J Nutr Health Aging"},{"issue":"4","key":"2035_CR197","first-page":"243","volume":"3","author":"H Hampel","year":"2016","unstructured":"Hampel H, O\u2019Bryant SE, Castrillo JI et al (2016) Precision medicine - the golden gate for detection, treatment and prevention of Alzheimer\u2019s disease. J Prev Alzheimers Dis 3(4):243\u2013259","journal-title":"J Prev Alzheimers Dis"},{"issue":"s1","key":"2035_CR198","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.3233\/JAD-179932","volume":"64","author":"H Hampel","year":"2018","unstructured":"Hampel H, Toschi N, Babiloni C et al (2018) Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology. J Alzheimers Dis 64(s1):S47\u2013S105","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2035_CR199","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/13697137.2017.1287866","volume":"20","author":"H Hampel","year":"2017","unstructured":"Hampel H, O\u2019Bryant SE, Durrleman S et al (2017) A precision medicine initiative for Alzheimer\u2019s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric 20(2):107\u2013118","journal-title":"Climacteric"},{"key":"2035_CR200","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.phrs.2018.02.014","volume":"130","author":"H Hampel","year":"2018","unstructured":"Hampel H, Vergallo A, Aguilar LF et al (2018) Precision pharmacology for Alzheimer\u2019s disease. Pharmacol Res 130:331\u2013365","journal-title":"Pharmacol Res"},{"issue":"1","key":"2035_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-181121","volume":"68","author":"H Hampel","year":"2019","unstructured":"Hampel H, Vergallo A, Perry G, Lista S, Alzheimer Precision Medicine Initiative (APMI) (2019) The Alzheimer Precision Medicine Initiative. J Alzheimers Dis 68(1):1\u201324","journal-title":"J Alzheimers Dis"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-020-02035-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T06:25:00Z","timestamp":1650522300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-020-02035-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,9]]},"references-count":201,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2035"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-02035-9","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,9]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"S.L. received lecture honoraria from Roche and Servier.H.H. is an employee of Eisai Inc. and serves as Senior Associate Editor for the Journal Alzheimer\u2019s & Dementia and does not receive any fees or honoraria since May 2019; before May 2019, he had received lecture fees from Servier, Biogen, and Roche; research grants from Pfizer, Avid, and MSD Avenir (paid to the institution); travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics; and consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation, and he also participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics, and Roche Diagnostics.He is co-inventor in the following patents as a scientific expert and has received no royalties:\n                      \n                      G.P., S.M., A.D.V., G.S., U.B., C.A., R.C., and F.B. declare that they have no conflicts of interest relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}